Prof. Löffler gewann Ende des Jahres 2012 den ASPIRE EUROPE Preis (dotiert mit 50.000 Euro)

Aspire Europe Award

The overall aim of this project is to determine the effect of antifungal drugs on the detection of molecular markers for invasive aspergillosis (IA) in patient samples. To achieve this objective, we perform an integrative and comprehensive approach, covering in vitro, in vivo and, the major focus, a prospective clinical study of the effects of antifungal treatment on PCR-based diagnostic methods.

Specifically the effect of antifungal drugs on the in vitro release of DNA and galactomannan (GM) is measured to determine the magnitude of drug effects on relevant biomarker detection. A murine model of IA is used to validate the in vitro results and allow optimisation of the detection methods.

The final objective is to see if the observations from in vitro and in vivo models can be used to improve detection of fungal DNA and GM in patient plasma and whole blood samples.

Results are determined for fungistatic (voriconazole, posaconazole as examples) as well as fungicidal (amphotericin B as example) drugs, respectively.

All data are generated using methods in line with the EAPCRI guidelines (White et al., 2010, White et al., 2011) and under the auspices of the EAPCRI Steering Committee. EAPCRI performs independent data reviews to ensure the quality of the findings.